ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER).
ISOLYTE P with 5% Dextrose provides electrolyte replacement and caloric supplementation. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes are essential for maintaining osmotic balance, acid-base equilibrium, and normal cellular function.
| Metabolism | Dextrose is metabolized via glycolysis and the Krebs cycle. Electrolytes are not metabolized but are excreted or reabsorbed. |
| Excretion | Renal excretion of free water and electrolytes; dextrose is metabolized to CO2 and water, with negligible biliary or fecal elimination. Approximately 50-70% of infused water is excreted renally within 24 hours, adjusted by ADH and renal function. |
| Half-life | Dextrose: rapid clearance, half-life ~1.5-2 hours in normoglycemic patients; prolonged in renal impairment or diabetes. Electrolytes follow homeostatic regulation with no defined terminal half-life. |
| Protein binding | Dextrose: negligible (<1%). Electrolytes: sodium and potassium are not protein bound; chloride, acetate, and gluconate are free in plasma. |
| Volume of Distribution | Dextrose: ~0.2 L/kg (limited to extracellular fluid initially); electrolytes distribute according to body water compartments: sodium ~0.2 L/kg (ECF), potassium ~0.4 L/kg (ICF). |
| Bioavailability | Intravenous: 100% (complete bioavailability). No oral formulation; oral dextrose has variable absorption. |
| Onset of Action | Intravenous: immediate (seconds to minutes) for volume expansion and electrolyte distribution; dextrose metabolism begins within minutes. |
| Duration of Action | Intravenous: 2-4 hours for volume effect; electrolyte and glucose effects persist as long as infusion continues; rapid redistribution after cessation. |
| Molecular Weight | Dextrose: 180.16 Da; Electrolytes: varies (e.g., Na+ 23 Da, K+ 39 Da, Mg2+ 24 Da, Cl- 35.5 Da, acetate 59 Da, gluconate 196 Da) |
Intravenous infusion. Adult dose: 1000-2000 mL over 24 hours, adjusted based on fluid and electrolyte needs. Typical rate: 125-150 mL/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-50 mL/min: Monitor electrolytes closely; reduce infusion rate if hyperkalemia or fluid overload. GFR <10 mL/min: Contraindicated if severe renal impairment with oliguria or anuria; use with caution and adjust volume based on residual renal function. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B and C: Monitor for fluid retention and electrolyte imbalances; adjust volume and rate accordingly. |
| Pediatric use | Weight-based: 20-100 mL/kg/day, adjusted for hydration status and maintenance needs. Maximum rate: 4-8 mL/kg/hour depending on age and clinical condition. |
| Geriatric use | Elderly patients: Use lower end of dose range due to decreased renal function and risk of fluid overload; monitor electrolytes and volume status closely. |
| 1st trimester | No evidence of fetal harm; intravenous electrolyte and glucose solutions are used when clinically indicated. Dextrose may cause maternal hyperglycemia; monitor blood glucose. Considered safe with appropriate monitoring. |
| 2nd trimester | No evidence of fetal harm; use when clinically indicated. Monitor maternal glucose and electrolytes to avoid imbalance. |
| 3rd trimester | No evidence of fetal harm; use when clinically indicated. Avoid excess dextrose to prevent neonatal hyperinsulinemia and hypoglycemia. Monitor maternal glucose. |
Clinical note
Comprehensive clinical and safety monograph for ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER).
| Placental transfer | Dextrose and electrolytes readily cross the placenta via simple diffusion and active transport. Concentrations in fetal blood equilibrate with maternal levels. No specific evidence of adverse effects from therapeutic use. |
| Breastfeeding | ISOLYTE P with Dextrose 5% is compatible with breastfeeding. The components are normal constituents of human milk. Administration to the mother does not pose a risk to the nursing infant. Monitor infant for any signs of electrolyte imbalance if high doses are used. |
| Lactation Rating | Safe |
| Teratogenic Risk | Dextrose 5% and electrolytes (Isolyte P) are generally considered to have low teratogenic risk. Dextrose solutions are essential for maintaining maternal glucose levels; severe electrolyte imbalances may pose risks. No specific teratogenic effects have been reported from the components at therapeutic doses. Trimester-specific risks: First trimester: No known teratogenicity. Second and third trimesters: Use is safe when indicated, but avoid hyperglycemia which may be associated with fetal macrosomia or neonatal hypoglycemia. |
| Fetal Monitoring | Monitor maternal blood glucose, serum electrolytes (sodium, potassium, chloride, bicarbonate), and fluid balance. For fetal monitoring, assess uterine activity and fetal heart rate patterns during infusion if indicated for maternal condition. In prolonged use, monitor for signs of fluid overload or electrolyte disturbances. |
| Fertility Effects | No known effects on fertility. Dextrose and electrolyte solutions are used for fluid and electrolyte maintenance and do not impair reproductive function. |
■ FDA Black Box Warning
None
| Serious Effects |
Hyperglycemia (unless appropriate hypoglycemic therapy is administered)Hypersensitivity to any componentClinically significant hyperkalemia (for potassium-containing formulations)Patients with acute intracranial hemorrhage (if containing dextrose, due to risk of hyperglycemia)Severe metabolic acidosis (unless corrected)Anuria or severe renal impairment (unless dialysis is available)
| Precautions | Risk of hyperglycemia, especially in patients with diabetes mellitus, Monitor serum electrolytes, glucose, and fluid balance, May cause fluid overload in patients with renal or cardiac impairment, In neonates, rapid administration may cause hyperinsulinemia and rebound hypoglycemia, Use with caution in patients with severe electrolyte disturbances |
| Food/Dietary | Food interactions are not clinically relevant as the drug is administered intravenously. However, oral intake may affect electrolyte levels; therefore, dietary intake of potassium, sodium, and other electrolytes should be considered when monitoring therapy. Avoid concurrent use with phosphate-containing oral products without medical advice due to risk of hyperphosphatemia. |
| Clinical Pearls | ISOLYTE P with DEXTROSE 5% is a balanced maintenance fluid containing multiple electrolytes including potassium, magnesium, and phosphorus. It is designed for pediatric patients or those requiring maintenance fluids with lower sodium content. Monitor serum electrolytes frequently, especially in renal impairment. This solution provides 5% dextrose, representing ~170 kcal/L, which can help prevent ketosis. Do not use in patients with hyperkalemia, severe renal failure, or uncorrected metabolic alkalosis. Infuse via central line only if peripheral access is inadequate due to potential phlebitis. |
| Patient Advice | This fluid is given intravenously to maintain hydration and electrolyte balance. · It contains sugar (dextrose) to provide calories. · Inform your healthcare provider if you have diabetes, kidney problems, or heart disease. · Report any signs of infection at the injection site, such as redness, swelling, or pain. · Tell your doctor if you experience muscle weakness, irregular heartbeat, or tingling sensations. · This medication may affect blood sugar levels; monitor if diabetic. |
Loading safety data…